Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Rating of “Buy” by Analysts

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) has earned a consensus rating of “Buy” from the eight research firms that are presently covering the stock, MarketBeat reports. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $21.00.

Several equities research analysts have issued reports on ZVRA shares. Cantor Fitzgerald reiterated an “overweight” rating on shares of Zevra Therapeutics in a research note on Friday, October 11th. JMP Securities initiated coverage on shares of Zevra Therapeutics in a research report on Tuesday, September 24th. They set an “outperform” rating and a $17.00 price target for the company. Guggenheim assumed coverage on Zevra Therapeutics in a research report on Monday, October 7th. They issued a “buy” rating and a $20.00 price objective on the stock. Roth Mkm upped their target price on Zevra Therapeutics from $19.00 to $21.00 and gave the stock a “buy” rating in a research report on Tuesday, September 24th. Finally, Maxim Group increased their target price on Zevra Therapeutics from $18.00 to $25.00 and gave the company a “buy” rating in a research note on Tuesday, September 24th.

Hedge Funds Weigh In On Zevra Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. grew its stake in Zevra Therapeutics by 3.6% in the first quarter. Vanguard Group Inc. now owns 1,704,006 shares of the company’s stock worth $9,883,000 after purchasing an additional 58,866 shares in the last quarter. Price T Rowe Associates Inc. MD bought a new position in Zevra Therapeutics during the 1st quarter worth approximately $64,000. Jacobs Levy Equity Management Inc. grew its position in shares of Zevra Therapeutics by 102.4% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 34,707 shares of the company’s stock worth $201,000 after acquiring an additional 17,557 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in shares of Zevra Therapeutics by 10.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 220,499 shares of the company’s stock valued at $1,080,000 after acquiring an additional 21,231 shares during the last quarter. Finally, Rhumbline Advisers raised its position in shares of Zevra Therapeutics by 17.9% during the 2nd quarter. Rhumbline Advisers now owns 56,874 shares of the company’s stock valued at $279,000 after acquiring an additional 8,619 shares in the last quarter. 35.03% of the stock is currently owned by hedge funds and other institutional investors.

Zevra Therapeutics Price Performance

ZVRA stock opened at $9.33 on Monday. The company has a market cap of $498.00 million, a PE ratio of -4.74 and a beta of 1.93. The company has a current ratio of 2.88, a quick ratio of 2.88 and a debt-to-equity ratio of 0.84. The stock has a 50-day moving average price of $8.35 and a two-hundred day moving average price of $6.82. Zevra Therapeutics has a 12-month low of $4.20 and a 12-month high of $9.76.

Zevra Therapeutics (NASDAQ:ZVRA) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.25). The firm had revenue of $3.70 million during the quarter, compared to analyst estimates of $5.04 million. Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. During the same period in the prior year, the firm earned ($0.40) earnings per share. As a group, research analysts predict that Zevra Therapeutics will post -1.96 EPS for the current year.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.